Subclinical thyroid disease

Efficacy of Low‐dose (2 millicurie) versus Standard‐dose (4 millicurie) Radioiodine Treatment for Cats with Mild‐to‐Moderate Hyperthyroidism

“…By definition, subclinical hypothyroidism is a biochemical diagnosis because few, if any, clinical features of thyroid failure are present 34, 35, 36, 37. Subclinical hypothyroidism is a common finding after radioiodine treatment for human patients with Graves’ disease and toxic nodular goiter 34, 35, 36, 37. In the present study, 1 in 5 cats treated with low‐dose 131 I and nearly 50% of cats treated with traditional 4 mCi 131 I were categorized as having subclinical hypothyroidism 6 months after treatment.…”

“…41,43 Furthermore, approximately 2-6% of humans with subclinical hypothyroidism will progress to overt hypothyroidism with each year after radioiodine treatment. 34,37,41 It is currently unknown if a similar progression from subclinical to overt hypothyroidism occurs in cats, or if some cats with subclinical or overt hypothyroidism will recover normal thyroid function (with normalization of serum TSH and T 4 concentrations) months to years after radioiodine treatment. Long-term follow-up studies are needed to classify the progression or resolution of iatrogenic thyroid damage in cats after radioiodine treatment.…”

Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity

“…Thyroid hormones regulate free fatty acid and triglyceride synthesis [26,27], and there is a feedback loop between TSH and thyroid hormones in the body [28]. Therefore, the role of thyroid hormones must be ruled out to observe the direct effect of TSH on triglyceride metabolism.…”

Symptoms of thyrotoxicosis, bone metabolism and occult atrial fibrillation in older women with mild endogenous subclinical hyperthyroidism

“…Among patients with endogenous subclinical hyperthyroidism (SCH), those aged ≥65 years and with serum TSH >0·1 mIU/l represent a group of great interest. These patients account for approximately 50% of cases of SCH and the need for treatment in this group is controversial . The decision to treat requires knowledge of the potential repercussions of SCH, including symptoms of thyrotoxicosis, changes in bone metabolism and bone mineral density (BMD) and atrial fibrillation (AF).…”